Prof Larry Anderson speaks to ecancer in an online interview for the IMW 2021 meeting about updated results from the KarMMa trial.
He explains that the trial looked at idecabtagene vicleucel (ide-cel), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM). The updated results gave longer-term follow-up data as well as breaking down outcomes by number of prior lines of therapy.
Prof Anderson reports that the results continue to demonstrate durable responses with ide-cel in heavily pretreated patients with RRMM.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.